**Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**

Published On: December 30, 2015 | Pages: 009 - 017

Author(s): Roberto Focaccia*, Rodolfo Ferreira de Mello, Patrícia Silva Montes and Flávio Martin Conti

Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to interferon (IFN). IFN-free treatments are now considered elective drugs for patients with chronic HCV. More than 90% of patients infected with HCV ge ...
with the IL28B Gene Polymorphisms

Published On: December 28, 2015 | Pages: 005 - 008

Author(s): Pavlina Dzekova Vidimliski, Igor G Nikolov, Nadica Matevska Geshkovska, Yana Boyanova, Nina Nikolova, Grigore Romanciuc, Dan Dumitrascu, Viktorija Caloska- Ivanova, Nenad Joksimovic, Krasimir Antonov, Lyudmila Mateva, Lionel Rostaing, Aleksandar Dimovski, Aleksandar Sikole*

Background: It has been shown that single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) gene were associated with sustained viral response following standard treatment of hepatitis C virus infection. Aim: The aim of the study was to evaluate the association between the SNPs near the IL28B gene and the response to the treatment of chronic hepatitis ...

DOI: 10.17352/ahr.000002